DUBLIN, Feb. 25, 2020 /PRNewswire/ -- Allergan plc,
(NYSE: AGN), a leading global pharmaceutical company with a more
than 70-year heritage in ophthalmology, will present new data from
investigational Bimatoprost Sustained-Release (SR) at the Annual
Meeting of the American Glaucoma Society (AGS) to be held in
Washington, D.C. Data from the
Phase 3 ARTEMIS studies will be presented during an oral session
and will provide visual field (VF) outcomes and effects of
Bimatoprost SR on disease progression in patients with open-angle
glaucoma (OAG). A New Drug Application (NDA) for Bimatoprost SR is
currently under review with the U.S. Food and Drug Administration,
and if approved, has the potential to be the first and only
biodegradable, intracameral implant indicated to reduce intraocular
pressure in patients with open-angle glaucoma or ocular
hypertension via a sustained-release drug delivery system.
"These exciting results presented at AGS reinforce our belief
that Bimatoprost SR is a transformative drug that has the potential
to change the treatment paradigm for people living with glaucoma,"
said Michael Robinson, M.D., Vice
President, Global Therapeutic Area Head, Ophthalmology, Allergan.
"There are 70 million people globally who are living with this
serious and sight-threatening disease that may result in blindness
and it is our commitment to ensure we are addressing their unmet
needs with innovative treatments like Bimatoprost SR."
In the same oral session, a separate presentation will feature
results from the first study to quantify the effect of greater
topical medication adherence on rate of glaucoma progression in a
real-world patient population.
Allergan will present eight abstracts, including two oral
presentations and six poster presentations (all noted in local
Eastern Time):
Poster Presentations (Friday, February
28, 7:00 – 5:00 PM):
- Effect of Bimatoprost SR on IOP in Patients Previously Treated
With 0, 1, or ≥2 Topical IOP-Lowering Medications: Results of Phase
3 Study at Primary Database Lock
-
- Authors: Craven, ER et al.
- Long-Term IOP Lowering After A Single Bimatoprost SR
Administration in a Phase 1/2 Study: Relationship to Early IOP
Response
-
- Authors: Brubaker, J et al.
- Bimatoprost Sustained-Release Implant (Bimatoprost SR)
Responder Rates in Patients With Glaucoma or Ocular Hypertension:
Phase 3 Study Results at Primary Database Lock
-
- Authors: Walters, T et al.
- Profile of IOP Response to Bimatoprost Sustained-Release
Implant (Bimatoprost SR) Before Added Treatment With Topical
Medication: Phase 3 Study Results
-
- Authors: Myers, JS et al.
- Targeted Delivery via Intracameral Administration Versus
Topical Dose of 14C-Latanoprost in Animal Models.
-
Poster Presentations (Saturday, February
29, 7:00 – 4:05 PM):
- Healthcare Resource Utilization and Costs Related to Ocular
Hypertension and Open-angle Glaucoma by Disease Severity
-
- Authors: Miller, E et al.
Oral Presentations (Saturday, February 29, 8:05 –
9:05 AM):
- Adherence to Topical Glaucoma Medications Decreases Rate of
Visual Field Progression Over Time
-
- Authors: Fong, D et al.
- Time: 8:05 – 8:17 AM
- Visual Field Outcomes in Open-Angle Glaucoma Patients Treated
With Bimatoprost SR in Phase 3 Evaluation: Results at Primary
Database Lock
-
- Authors: Medeiros, F et al.
- Time: 8:17 – 8:29 AM
About Allergan Eye Care
As a leader in eye care,
Allergan has discovered, developed, and delivered some of the most
innovative products in the industry for more than 70 years.
Allergan has launched over 125 eye care products and invested
billions of dollars in new treatments for the most prevalent eye
conditions including glaucoma, ocular surface disease, and retinal
diseases such as diabetic macular edema and retinal vein occlusion.
Our eye care pipeline includes 13 additional agents for multiple
ocular conditions.
Our commitment to the well-being of patients is also reflected
in social responsibility. Allergan, The Allergan Foundation and The
Allergan International Foundation support more than 150
organizations around the world working to improve lives and
communities. We remain steadfast in helping eye care providers
deliver the best in patient care through innovative products and
outreach programs.
About Allergan plc
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland,
is a global pharmaceutical leader focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world. Allergan markets a portfolio of leading brands
and best-in-class products primarily focused on four key
therapeutic areas including medical aesthetics, eye care, central
nervous system and gastroenterology. As part of its approach to
delivering innovation for better patient care, Allergan has built
one of the broadest pharmaceutical and device research and
development pipelines in the industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives every day.
For more information, visit Allergan's website at
www.Allergan.com.
Forward-Looking Statement
Statements contained in this
press release that refer to future events or other non-historical
facts are forward-looking statements that reflect Allergan's
current perspective on existing trends and information as of the
date of this release. Actual results may differ materially from
Allergan's current expectations depending upon a number of factors
affecting Allergan's business. These factors include, among others,
the difficulty of predicting the timing or outcome of FDA approvals
or actions, if any; the impact of competitive products and pricing;
market acceptance of and continued demand for Allergan's products;
the impact of uncertainty around timing of generic entry related to
key products, including RESTASIS®, on our financial results; risks
associated with divestitures, acquisitions, mergers and joint
ventures; risks related to impairments; uncertainty associated with
financial projections, projected cost reductions, projected debt
reduction, projected synergies, restructurings, increased costs,
and adverse tax consequences; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2019. Except as expressly required by law, Allergan
disclaims any intent or obligation to update these forward-looking
statements.
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Manisha Narasimhan,
PhD
|
|
(862)
261-7162
|
|
|
|
Media:
|
|
Fran
DeSena
|
|
(862)
261-8820
|
|
|
|
Lisa Kim
|
|
(714)
246-3843
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-to-present-new-data-for-investigational-bimatoprost-sustained-release-at-american-glaucoma-society-annual-meeting-301010115.html
SOURCE Allergan plc